Biotique Systems Announces Three Initial Customers for its BLIS Genomic Integration Solution.Business Editors and Health/Medical Writers BIOWIRE2K EMERYVILLE, Calif.--(BW HealthWire)--July 9, 2002 Biotique Systems, Inc. today announced that Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Company, Berlex Laboratories Introduction Berlex Laboratories, Incorporated is a research-based pharmaceutical company headquartered in Montville, New Jersey with operations in Wayne, New Jersey; Bothell, Washington; Seattle, Washington; and Richmond, California. , Inc., a subsidiary of Schering AG, and a biochip biochip Small-scale device, analogous to an integrated circuit, constructed of or used to analyze organic molecules associated with living organisms. One type of theoretical biochip is a small device constructed of large organic molecules, such as proteins, and capable of manufacturer are among the initial customers for the Biotique Local Integration Solution (BLIS BLIS Blind Spot Information System (Volvo) BLIS Building Lifecycle Interoperable Software BLIS Blood Information System BLIS Base Level Inquiry System BLIS Basic Load Inspection System BLIS Bell Laboratories Interpretive System ) and extension products. BLIS is a data integration, analysis and visualization platform that enables pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. to expedite target discovery and refinement using the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. as a reference template. "BLIS allows any biologist working in drug discovery at Bristol-Myers Squibb Company to visualize our proprietary annotations to human genomic data," said Dr. Dan Davison, associate director of bioinformatics, applied genomics applied genomics Molecular genetics Molecular medicine The use of genetic information to diagnose, prognosticate and manage disease, based on the techniques of PCR, real time-PCR, DNA sequencing, and gene rearrangement studies for leukemia and lymphoma. , Bristol-Myers Squibb Company. "We wanted to implement public genomic data and genome browsers in-house, but this system eliminates the need for us to manage and update this data by providing a commercially supported platform for the integration of our proprietary data with the public data. As a result we can visualize much more genomic information than we could before." "If you want to get work done with the human or other genomes today, I would recommend Biotique's tools and services," said Dr. Hugh Salamon, scientific manager, computational biology Not to be confused with Biologically-inspired computing. Computational biology is an interdisciplinary field that applies the techniques of computer science, applied mathematics, and statistics to address problems inspired by biology. at Berlex Laboratories. "BLIS is very powerful and accessible. We are able to do a lot with this system, and to work at a very practical level with our data and see it in its genomic context. This is the first step to properly integrating genetic epidemiology with the rest of bioinformatics for drug discovery," he said. Berlex originally licensed the BLIS system in October 2001, and has recently enhanced its investment in the BLIS platform by licensing Biotique's comparative genomics Comparative genomics is the study of relationships between the genomes of different species or strains. Comparative genomics is an attempt to take advantage of the information provided by the signatures of selection to understand the function and evolutionary processes that act on extension product for model organism genome analysis and biochip design. "BLIS is ideal for organizations that have large amounts of proprietary target data and need a way to organize, analyze and share this knowledge," said Stephen Sanders, chairman and chief executive officer, Biotique Systems. "We are delighted that major pharmaceutical and biotechnology companies are already recognizing the value in our system." In addition to Bristol-Myers Squibb and Berlex Laboratories, an undisclosed biochip manufacturer has also licensed the BLIS system and Biotique's services to enhance its chip design process. BLIS runs on Unix and Linux platforms. Extensive optimization has been done for the IBM eServer xSeries system - the most powerful thin server in the industry. Biotique Systems became an IBM (International Business Machines Corporation, Armonk, NY, www.ibm.com) The world's largest computer company. IBM's product lines include the S/390 mainframes (zSeries), AS/400 midrange business systems (iSeries), RS/6000 workstations and servers (pSeries), Intel-based servers (xSeries) Business Partner in March, 2002. Biotique Systems, Inc. was founded in 2001 to solve critical issues in the life sciences. The Company provides decision support tools and services for the emerging field of pharmacogenomics. Biotique's pharmaceutical and biotechnology customers have adopted the Company's solutions to integrate their proprietary, third-party and public data sources, optimize biochip designs and other assays, and perform comparative genomic analysis. As a result, Biotique is enabling the next generation of genomic discovery. For more information, contact Biotique Systems, Inc. at 510/595-3110 or e-mail inquire@biotiquesystems.com or visit http://www.biotiquesystems.com. Note to Editors: Biotique Systems, BLIS and the Biotique logo are trademarks of Biotique Systems, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion